Abstract Lung cancer remains the leading cause of cancer-related death and economic burden worldwide. Despite the heavy toll of lung cancer, multiple new advances have improved patient outcomes, largely through precision medicine and targeted therapy. The associated rising economic burden however may impact the uptake of novel therapeutic agents in lung cancer, thereby limiting patient access. This article identifies and reviews economic evaluations of targeted agents in lung cancer in the era of precision medicine. Articles evaluating biomarker-directed test-and-treat strategies are also reviewed to evaluate the cost impact of novel therapeutic agents at a population level. The Quality of Health Economic Studies instrument is applied to assess the quality of included studies. Fortysix studies are reviewed and encompass studies of epidermal growth factor receptor inhibitors and monoclonal antibodies, anaplastic lymphoma kinase inhibitors, vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors and immunotherapy (programmed death-1 inhibitors). Key factors influencing results of economic analyses include comparators chosen, perspective used, magnitude of clinical benefit, utility weighting of outcomes and drug acquisition costs. Biomarker-driven decision making should be integrated into cost evaluations given the important role of molecular testing for individualising treatment for non-small-cell lung cancer. We conclude that despite major clinical advances in lung cancer therapeutics, cost remains an important consideration in the adoption of novel therapies.
and breast cancer combined [2] . Despite a historically poor prognosis, rapid evolution of the scientific understanding of lung cancer and the development of highly effective new treatments are changing the face and cost of this highly prevalent and deadly disease.
Treatment options for advanced non-small-cell lung cancer (NSCLC) have rapidly evolved over the past 10 years [see Appendix 1 in the Electronic Supplementary Material (ESM)]. In particular, greater understanding of the molecular mechanisms of lung cancer pathogenesis has resulted in a paradigm shift towards a precision medicine approach in NSCLC. Tyrosine kinase inhibitors (TKIs) directed towards molecular drivers including epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements have resulted in improved clinical outcomes in selected patient populations, compared with conventional chemotherapy [3] [4] [5] . Additional biomarkers that derive subgroups that benefit from targeted therapy are rapidly expanding, including patients with ROS-1 translocations, BRAF V600E mutations, MET mutations or amplification in tumours. Immunotherapy has also emerged as a new standard therapy that improves patient outcomes through targeting of the programmed death-1 (PD-1) axis [6] [7] [8] . Combination immunotherapy regimens are under study and may add to single-agent PD-1 axis inhibition in the near future. Other treatments have also demonstrated improvements over standard chemotherapy alone in selected populations, including agents targeting vascular endothelial growth factor (VEGF) and VEGF receptor tyrosine kinase [6] [7] [8] [9] .
Despite the major advances in patient outcomes with novel therapies, the high costs of these agents are a major limiting factor in their uptake by healthcare authorities worldwide. In addition, as the precision medicine approach in lung cancer evolves, companion diagnostic assays for targeted therapies may also add significantly to overall costs of treatment [10] . Therefore, national regulatory agencies and policy makers, such as the Canadian Agency for Drugs and Technologies in Health and the National Institute for Health and Care Excellence (NICE), routinely conduct health technology assessments to evaluate cost effectiveness prior to recommending public funding for clinically important novel agents [11, 12] .
The use of incremental cost-effectiveness ratios (ICER), estimates of budget impact and prioritisation frameworks have all emerged as key components of drug funding decisions. A key challenge is how to balance cost with benefit, justice and compassion, among other factors. While the ICER is used to aid payers in funding decisions, jurisdictions have a wide variation of acceptable cost-effectiveness ratio thresholds. These vary with resource constraints, budget impact, public sympathy and available treatment alternatives [13] . However, a frequently cited threshold for willingness to pay in the oncology literature is US$100,000/quality-adjusted life-year (QALY) in developed countries [14] . In many publically funded healthcare systems, reimbursement decisions drive patient access to novel treatments and their associated clinical benefit. This review aims to summarise economic considerations of novel therapies for lung cancer in the era of precision medicine, including recently published studies of cost in this area.
Methods
A literature search of PubMed, EMBASE, MEDLINE and the National Health Service Economic Evaluation Database was conducted in October 2016. The search included studies published in English between 2000 and 2016. The following search terms were used: NSCLC, targeted therapy, cost-effectiveness, cost-utility, EGFR inhibitors (gefitinib, erlotinib, afatinib, osimertinib), ALK inhibitors (crizotinib, alectinib, ceritinib, lorlatinib), VEGF-targeted monoclonal antibodies (bevacizumab, cetuximab, necitumumab), PD-1 inhibitors (nivolumab, pembrolizumab). In addition, a hand search was conducted to identify any relevant studies. All publications were reviewed independently by two authors (H.A and C.L.). Only original studies published in full text were included.
The Quality of Health Economic Studies (QHES) instrument was used to evaluate the quality of the included studies (see Appendix 2 of the ESM). The QHES is a validated instrument designed to measure the quality of health economic analyses [15] . Each article was evaluated for quality in 16 specific criteria and scored between 0 and 100, where 0 represents lowest quality and 100 represents highest quality. Studies were scored by deducting points from the maximum score of 100 for each criterion not addressed, and classified into the following groups: (1) extremely poor quality (0-24); (2) poor quality ; (3) fair quality ; and (4) high quality (75-100) [15] . The QHES evaluation was conducted independently by two authors (H.A. and C.L.). Any discrepancies in scores were reviewed and harmonised by consensus discussion. Only studies with at least 'fair quality' were included.
Results
After exclusion of duplicates, abstracts and unrelated articles, a total of 46 full-text articles fulfilled the inclusion criteria and were included in the QHES review. Of these, 41 economic studies were scored to be of high quality and the other five of fair quality (see Appendix 3 of the ESM).
We present results here by molecular subtype and class of agent.
Epidermal Growth Factor Receptor (EGFR) Targeted Agents
The epidermal growth factor is commonly expressed in NSCLC. However, with the development of EGFR-targeted TKIs, it was discovered that a selected subgroup of patients had dramatic and unexpected anti-tumour response and prolonged benefit. Subsequent investigation led to the discovery of activating EGFR mutations. Over the course of a decade, these agents progressed from being evaluated in heavily pretreated patients without molecular selection [16] to patients with treatment-naïve advanced lung cancer with EGFR mutant tumours [4, 17] and even in the adjuvant or preventive setting [18] .
EGFR Testing and Biomarker-Driven Targeted Treatment
Molecular profiling is therefore a crucial step in selecting patients most likely to derive benefit from targeted therapies. It requires infrastructure and funding to obtain cancer samples (biopsies) and perform molecular testing in a timely manner to identify those most likely to benefit from treatment. Several studies have examined the economic implications of targeted treatment algorithms, accounting for the need for initial population-based molecular testing to aid in patient selection. Economic analyses use different methods to incorporate (or not incorporate) the cost of molecular selection into therapy. For example, a test-and-treat strategy compares two approaches. The first is to test for the target biomarker and treat those with the biomarker with the novel targeted therapy while those without receive standard treatment (usually chemotherapy). This is compared to the previous standard where no patients received testing nor targeted therapy (Table 1) . Thus, key drivers of cost with a precision medicine approach include drug cost but also the cost of companion molecular testing, particularly if the assay is expensive and the population to be tested is large, such as in lung cancer. Published studies that evaluated a test-and-treat strategy have yielded different costs, largely because of the use of different agents, comparators and healthcare systems. Some even delve into the complexity of targeted therapy in the real-world setting, where many patients do not have sufficient tissue for biomarker analysis. Thus, while these vary, they all do support the incremental benefit of EGFR TKIs in those with EGFR mutant lung cancer. A German study evaluated initial erlotinib in patients with advanced EGFR mutant lung cancer modelled using a 10-year time horizon [19] . The ICER for the targeted treatment strategy was €15,577/QALY. However, cross-validation of health utility estimates with updated German data increased the ICER to €58,000/QALY. This difference was driven by assigning lower utility values for progressive disease vs. progression-free survival, resulting in lower incremental QALY gains than originally estimated. In Asia, EGFR mutant lung cancer is significantly more common (40% of advanced lung adenocarcinoma vs. 15% in Western populations). A study from Singapore examined first-line gefitinib and assumed that 60% of individuals tested positive for EGFR mutations [10] . The targeted strategy was cost saving and dominant over a non-targeted strategy of no testing with first-line chemotherapy and second-line gefitinib. It is important to note that in Singapore, because of the high frequency of mutations, all patients eventually receive the targeted therapy as part of standard practice. This differs from non-Asian jurisdictions where most patients would receive chemotherapy. Cost savings of SGD$2400 and an increase of 0.04 QALY were reported for the targeted treatment strategy, largely driven by avoiding gefitinib treatment costs for patients with wildtype EGFR. A study conducted in Japan assumed that 32% of patients tested positive and used a time horizon of 5 years [20] . The targeted testing and treatment strategy had incremental costs of ¥122,000 and 0.036 QALY, resulting in an ICER of ¥3.38 million/QALY. In a one-way sensitivity analysis, the cost of gefitinib had the greatest impact on the ICER, outweighing the impact of the EGFR mutation rate. This theme is repeated in multiple other economic analyses of targeted agents of lung and other cancers, with drug acquisition cost emerging as the key driver of cost utility.
An American study delved deeper into real-world practice, and examined multiple mutation testing strategies including no testing, testing only for patients with adequate available tissue and testing for all with repeat biopsies if tissue was insufficient (at least 15-40% of patients with advanced NSCLC) [14] . Erlotinib was used as a first-line treatment for patients who were EGFR mutation positive, and was compared against three commonly used chemotherapy regimens in USA: carboplatin/paclitaxel, carboplatin/pemetrexed and carboplatin/pemetrexed/bevacizumab, which vary widely in cost. Using a decision analytic model that accounted for potential repeat biopsies in up to 15% of patients, the ICERs for erlotinib compared with carboplatin/paclitaxel was US$122,234/QALY, US$103,132/ QALY with carboplatin/pemetrexed and US$44,036/QALY with carboplatin/pemetrexed/bevacizumab. The strategy of testing for EGFR mutations, performing repeat biopsy when necessary and treatment with erlotinib for patients who were EGFR mutation was deemed to be appropriate, but assumes that payers would fund the triplet combination including pemetrexed and bevacizumab, both costly drugs prior to patent expiry.
First-Line Tyrosine Kinase Inhibitors (TKIs) in Patients Who are EGFR Mutation Positive
Epidermal growth factor receptor TKIs have emerged as the initial treatment of choice for patients with advanced EGFR mutant lung cancer, with clear benefits over chemotherapy with respect to tumour response or shrinkage, time to progression or cancer growth, symptom improvement, quality of life and quality-adjusted survival [4, 17] . Because of high rates of crossover to these highly active agents from the control arm of chemotherapy in all trials, the impact on survival has been obscured. However, studies have tried indirectly to estimate the survival gain, ranging from a median of 3 months to substantially longer [21] . Current first-line options include gefitinib, erlotinib, afatinib and dacomitinib for first-line treatment in patients with sensitising EGFR mutations. Economic analyses of these agents have been completed or are underway in multiple European, Asian and North American settings. Unless otherwise stated the outcome measure for the ICER is the QALY Currency conversion is estimated based on the historical exchange rate provided based on the period average from the month of publication of the article. Currency exchange rates were obtained from: http://www.oanda.com/currency/historical-rates/ BSC best supportive care, DOC docetaxel, ERL erlotinib, GEF gefitinib, ICER incremental cost effectiveness ratio, LYG life-year gained, NSCLC non-small-cell lung cancer, PEM pemetrexed, QALY quality-adjusted life-year
In the UK, NICE has conducted two cost-utility analyses of gefitinib as first-line treatment. The first study, published in 2010 based on data from the pivotal study by Mok et al. [4] , compared gefitinib with doublet chemotherapy and reported an ICER of £35,700/QALY [22] . Additional studies were published, based on de novo economic modelling using prices for drugs listed in the British National Formulary, and when comparing gefitinib with cisplatin/paclitaxel reported an ICER of £57,440/QALY [23] . When formulary prices were substituted with mean prices negotiated by the National Health Service, gefitinib was compared with the lowest cost platinum doublet, carboplatin/paclitaxel and reported an ICER of £85,848/QALY. However, most of these patients would have been treated with pemetrexed/platinum in the rest of the world, which is more costly but potentially has superior outcomes in adenocarcinoma. A European analysis, primarily in Spain, Italy and France, compared erlotinib with standard first-line chemotherapy in patients with EGFR mutations [24] . A Markov model simulated outcomes beyond the trial period and costs were determined separately for each of the three countries. Erlotinib was the dominant strategy yielding costs savings of €7,870, €17,311 and €19,364, respectively, and a gain of 0.117 QALY. Given the similarity in drug acquisition costs among the EGFR TKIs, these variations in costs savings between countries are likely related to different costs of comparator agents and differential discounting of outcomes.
A study from the perspective of the Chinese healthcare system compared erlotinib with carboplatin/gemcitabine [25] . The estimated cost of erlotinib was US$1971 per cycle; however, practice at the time allowed patients to receive erlotinib free of charge from the manufacturer after 5 months of treatment. The authors reported an ICER of US$30,455/life-year gained (LYG) and US$85,927/QALY. Drug acquisition was the main driver of cost, and disease progression had the greatest impact on the ICER in the oneway sensitivity analysis. A study from Hong Kong compared two TKIs erlotinib and gefitinib as first-line treatment in patients with the EGFR mutant, using indirect comparison of outcomes from four randomised trials conducted in Asia [26] . This study concluded that erlotinib yielded longer progression-free survival than gefitinib, with an associated cost per progression-free LYG of $306,773 HKD, and cost per QALY gained was $485,619 HKD favouring erlotinib over gefitinib. However, these results are not generalisable as data suggest the outcomes of these two agents are similar, save for minor differences in the toxicity profiles [27] .
An American study compared both erlotinib and a second-generation inhibitor afatinib with cisplatin/pemetrexed chemotherapy for patients who were EGFR mutation positive [28] . Trial data from EURTAC [29] and LUX-Lung 3 [30] were incorporated into a Markov model with costs estimated from Medicare and Medicaid databases. Both erlotinib and afatinib were cost effective when compared with cisplatin/pemetrexed. Erlotinib was more cost effective compared with afatinib with an ICER of US$61,809/ QALY gained. Again, these TKIs have not been compared head to head in prospective trials in the EGFR mutationpositive patient population. Thus, this ICER seems unlikely generalisable, given only minor differences in drug acquisition costs, no demonstrable difference in outcomes and a minor increase in toxicity that would not result in major resource utilisation differences.
Second-Line TKI in Patients Who are EGFR Mutation Positive
Older studies have examined TKI use in second-line settings specific to patients who were EGFR mutation positive. Many of these are based on exploratory molecular subgroup analyses of larger trials in unselected populations. Of note, the comparator arm of second-line chemotherapy has less activity than first-line chemotherapy and has significant toxicity. Horgan et al. reported a costconsequence analysis of gefitinib vs. docetaxel in the Canadian context based on data from the international randomised INTEREST trial [31] . The incremental cost for gefitinib compared with docetaxel in the EGFR mutationpositive subgroup was Can$5831, but progression-free survival was longer and utility scores were higher. In this small subgroup, gefitinib was the preferred strategy in 74% of Monte Carlo simulations. Another Canadian study by Bradbury et al. used data from the NCIC CTG BR.21 trial comparing erlotinib with best supportive care [32] . In the entire unselected study population, the ICER for erlotinib was Can$94,638/LYG. In the EGFR mutation-positive subgroup, the ICER was even higher at Can$138,158, owing primarily to the greater duration of therapy with minimal survival advantage (2.6 months) with erlotinib therapy in this subgroup. These studies highlight the importance of larger sample sizes of patients with the known target biomarker, and the use of quality-adjusted survival in analyses of targeted therapy. Subsequent studies in this area have focused on selection patients by EGFR genotype.
Maintenance EGFR TKI in Unselected Patients
Despite multiple jurisdictions approving and funding maintenance EGFR TKIs after chemotherapy for advanced disease, this approach has later been demonstrated not to improve survival and has been withdrawn in many jurisdictions including USA, Canada and Europe. However, multiple studies of maintenance EGFR TKIs in unselected patients have been conducted, highlighting the unmet need for better treatment in this group and the marginal benefits of TKI maintenance therapy. Costs of erlotinib and pemetrexed as maintenance treatment after first-line therapy were compared in multiple European countries, specifically France, Germany, Italy and Spain [33] . Costs reported included cost of drug acquisition, administration and managing adverse events. The total monthly cost of erlotinib was reported as €2140, €2732, €1518 and €2048, respectively, and total monthly cost of pemetrexed as €3453, €5534, €2921 and €3164, respectively. The authors reported that erlotinib was cost saving relative to pemetrexed. In this analysis, the survival benefit was similar between groups, although in other studies the survival advantage for pemetrexed maintenance treatment is greater than for erlotinib [34] . Erlotinib maintenance therapy was also evaluated in the UK based on data from the SATURN trial [35] . The NICE evidence review revised the initial manufacturer submission and reported an ICER for stable disease of £44,812 per QALY in the squamous population and £68,120 per QALY in the non-squamous population. When erlotinib was compared with pemetrexed, the ICER was £84,029. These were above the NICE threshold for cost effectiveness, resulting in a recommendation against funding erlotinib in this setting. Finally, an American study evaluated pemetrexed as first-line maintenance therapy in patients with the non-squamous type, with a secondary analysis comparing pemetrexed with erlotinib [36] . Drug costs were based on Medicare reimbursement rates and retrospective claims analysis. Among all patients regardless of histological subtype, the ICER for pemetrexed compared with erlotinib was US$312,341/ QALY. However, when limited to the non-squamous histological subtype, the ICER improved to US$150,260. This again emphasised the importance of appropriate patient selection for maintenance therapy based on histological subtype.
EGFR TKIs in Unselected Patients
Although EGFR TKIs are recommended primarily in patients with EGFR mutation-positive lung cancer, many studies have been performed without molecular selection.
In the first-line setting, Khan et al. reported a cost analysis of treatment of patients enrolled in the TOPICAL trial comparing erlotinib with placebo in elderly patients in the UK considered unfit for chemotherapy [37] . Patients were not molecularly selected in the trial and the clinical benefit from this approach was not deemed to be clinically significant. The ICER reported was £202,571/QALY among all patients. In the subgroup of patients developing rash within 28 days, a surrogate for clinical benefit, the ICER was £56,770/QALY. However, this analysis is clearly no longer relevant in the contemporary setting where only patients with EGFR mutation-positive disease are selected for first-line EGFR TKI therapy.
In the second-line setting, an American analysis compared erlotinib, docetaxel and pemetrexed in unselected patients [38] . Although data from clinical trials were used, a lack of a head-to-head comparison among these treatments was a major limitation and the authors assumed that overall survival and progression-free survival were equivalent for all three treatments. The estimated annual healthcare costs of erlotinib, docetaxel and pemetrexed were US$37,000, US$39,100 and US$43,800, respectively. A Canadian analysis of the BR.21 trial reported an ICER of Can$94,638/LYG for erlotinib compared with best supportive care [32] . A separate Canadian analysis of the INTEREST trial reported an incremental cost for gefitinib compared with docetaxel of Can$5161 over the entire duration of treatment [31] . The impact on QALY was not reported. An additional Canadian study based on a retrospective analysis of provincial data compared erlotinib with best supportive care in the third-line setting using a historical control group for comparison [39] . The ICER reported was Can$36,838/LYG, again with no reporting on QALY gains.
Emerging Agents
Novel agents targeting resistance mutations are being developed in patients who have not responded to EGFR TKI therapy. Approximately 60% of these patients develop an emergent T790M resistance mutation. Osimertinib is a recently approved third-generation TKI that targets T790M mutant lung cancer and has demonstrated superiority compared with chemotherapy in the second-line setting after initial TKI failure [5] and in the first-line setting [40] . These agents are potentially less toxic than first-and second-generation inhibitors. Economic analyses of pivotal trials for third-generation TKIs are not yet reported, but are expected in the near future. Combination treatment strategies of EGFR TKIs with other treatment classes including chemotherapy or immuno-oncology agents are also ongoing and will pose key challenges for how to better select patients in a cost-efficient manner and ensure drug acquisition costs are affordable.
Anaplastic Lymphoma Kinase (ALK) Targeted Agents
Approximately 2-3% of patients with advanced lung cancer have ALK-rearranged lung cancer. Most of these patients are younger and never smokers, and drug development in this cancer type has been highly efficient with four drugs approved from 2011 until 2017. Like EGFR mutant lung cancer, it is critical to identify ALK rearrangements in patient tumours to facilitate biomarker-driven treatment decisions. A variety of methods that have been developed for ALK molecular analysis, including relatively inexpensive immunohistochemistry (IHC) testing, which can be deployed on a population-wide basis, to more expensive sequencing or other assays such as fluorescence in situ hybridisation (FISH).
ALK Testing and Biomarker-Driven Targeted Treatment
An interesting study conducted in USA highlighted the issue of the costs of molecular testing and relevance of target frequency in economic evaluation [41] . Immunohistochemistry and FISH were both evaluated, with reported ICERs for screening all patients with advanced NSCLC of adenocarcinoma subtype at US$24,720/QALY with IHC and US$46,144/QALY with FISH (Table 2) . However, limiting testing to an enriched population based on clinical parameters (patients with adenocarcinoma, never smoking, EGFR and KRAS wild type) increased the prevalence of ALK rearrangements in the population, improving the ICER to US$2548/QALY and US$4756/ QALY, respectively. At an estimated prevalence of ALK rearrangement in 5% or more of patients, drug costs were the major driver overall, although true drug costs were not used in the analysis. In the first-line treatment setting, a Canadian study modelled an individualised treatment strategy with ALK testing based on screening IHC followed by confirmatory FISH for positive screening tests [42] . Re-biopsy probabilities and costs were incorporated into the model, and clinical benefit data were extrapolated from studies of crizotinib in the second-line setting as first-line studies had not been published at the time. The reported ICER for the individualised test-and-treat strategy was Can$255,970/ QALY compared with standard therapy with no testing and no crizotinib treatment. The authors reported that in the setting of high drug costs and low biomarker frequency, the individualised testing strategy followed by crizotinib treatment was not cost effective. The main driver was drug cost.
Second-Line TKI in ALK Rearranged Patients
An analysis of ceritinib, a second-generation TKI for patients who did not respond to first-line therapy with crizotinib in a Canadian population has been reported [43] . A 4-year time horizon was used in a partitioned model, along with clinical data from the single-arm ceritinib trials ASCEND-1 [44] and ASCEND-2 [45] trials as randomised trial data were not yet available at that time. Multiple comparator regimens were used, including best supportive care and pemetrexed chemotherapy, with reported ICERs of Can$149,117/QALY and Can$80,100/QALY respectively. The study concluded that ceritinib could be considered as potentially cost effective in this setting. Unfortunately, drug funding in Canada for second-generation ALK TKIs remains delayed, initially owing to the lack of randomised data against the standard comparator treatment and more recently because of drug acquisition costs [46].
Emerging Agents
In addition to ceritinib, multiple second-generation ALK TKIs have now been approved in the setting of crizotinibfailure, including alectinib and brigatinib. Alectinib has also been approved in the first-line setting based on the recent ALEX trial demonstrating superior response, disease control and toxicity profile compared with crizotinib [47] . Sequencing of these agents remains an area of significant knowledge gap. The ability to generate randomised data given the breadth of agents available is waning, thus many of these gaps will not be filled. However, these agents are Unless otherwise stated the outcome measure for the ICER is the QALY Currency conversion is estimated based on the historical exchange rate provided based on the period average from the month of publication of the article. Currency exchange rates were obtained from: http://www.oanda.com/currency/historical-rates/ BSC best supportive care, FISH fluorescence in situ hybridisation, ICER incremental cost-effectiveness ratio, IHC immunohistochemistry all highly active but also very costly. Thus, evaluating cost relative to benefit and ensuring access to these agents for patients through public funding are important challenges.
Vascular Endothelial Growth Factor Targeted Agents
Angiogenesis has long been established as a hallmark of cancer, and supports new blood vessel formation in growing cancers, as well as promotion of metastatic spread throughout the body. Angiogenesis inhibitors have been widely studied but despite signals of enhanced activity when added to standard chemotherapy, no reliable biomarker has been found for this class of agents in lung and many other cancers. Multiple studies have evaluated adding the VEGF-targeted monoclonal antibody bevacizumab to platinum doublet chemotherapy in the first-line setting. Conflicting clinical outcomes have been reported, with one positive pivotal study [48] improving median progressionfree survival in advanced disease by 2 months while another study did not demonstrate similar benefit [49] . Studies of bevacizumab in combination with cisplatin/ gemcitabine compared against cisplatin/pemetrexed used more expensive chemotherapy in the comparator and reported ICERs of 34,064,835 Won/LYG in Korea, NT $1,607,960/LYG in Taiwan and €34,919/LYG in Italy (Table 3 ) [50, 51] . Studies in USA report ICERs ranging from US$559,610 to $1,006,065/QALY depending on the comparator regimen [52, 53] . This variability highlights the use of multiple comparator regimens of differing cost and the modest survival benefit gained by bevacizumab and its high cost during patent protection. Interestingly, while bevacizumab is still used in USA for lung cancer, its use has decreased over time and not been taken up in other countries to a significant extent, even after patent expiry. Two more angiogenesis inhibitors have been demonstrated in randomised trials to yield a modest benefit when added to second-line docetaxel chemotherapy vs. chemotherapy alone [54, 55] . Ramucirumab is a monoclonal antibody that targets the VEGF receptor and showed modest survival gain when added to second-line chemotherapy in all pretreated advanced NSCLC [54] . No biomarker has been identified, and while some jurisdictions have approved it for use in lung cancer, others have not based on the lack of major improvement in clinical outcomes. Another angiogenesis inhibitor, nintedanib, is a multi-targeted oral VEGFR TKI, which has also shown modest improvement in survival when added to secondline chemotherapy in the adenocarcinoma subgroup of patients [55] . An economic analysis conducted in Spain evaluated nintedanib with docetaxel vs. docetaxel alone in the second-line setting, reporting ICER in an unselected overall population of €134,274/QALY and in the adenocarcinoma subgroup of €40,886/QALY [56] . This once again highlights the importance of patient selection based on histological subtype; however, uptake has been limited by the modest gain in survival and use of subgroup analysis.
Monoclonal Antibodies in
Advanced Non-SmallCell Lung Cancer
Agents Targeting the EGFR Pathway
Multiple monoclonal antibodies targeting EGFR in lung cancer have been studied. Most, such as cetuximab, have not been adopted for use but necitumumab was recently approved by the US Food and Drug Administration (FDA) based on a modest improvement in survival first line in patients with advanced squamous lung carcinoma [9] . A Swiss study reported on adding cetuximab to first-line doublet chemotherapy for patients with EGFR overexpression in the context of the FLEX cetuximab trial [57] .
The clinical benefit was modest at best despite enrichment by the selected biomarker, and the ICER was €376,205/ QALY. Adding cetuximab was considered to be not cost effective, in keeping with the European Medicines Agency recommendation against the use of cetuximab in NSCLC. Two studies have explored cost evaluations of necitumumab. The first was conducted in USA prior to FDA approval and reported multiple possible scenarios depending on drug pricing [58] . When necitumumab costs were set at US$350 per cycle, the corresponding ICER was US$49,493/QALY. At the other extreme, drug cost set at US$1850 per cycle corresponded to an ICER of US$198,750/QALY. Following FDA approval and release of pricing information, a NICE appraisal reported ICERs of £110,248/QALY for the entire study population, and £57,725/QALY for the western European subgroup [59] . Necitumumab was not recommended as a cost-effective use of resources in the UK. Again, uptake of necitumumab use has been limited primarily by the lack of dramatic clinical benefit for patients, and is strengthened by evidence of cost ineffectiveness.
Agents Targeting the Programmed Death-1 Pathway
Another paradigm shift in lung cancer has occurred with the introduction of immunotherapy, namely PD-1 checkpoint inhibitors. These agents activate anti-cancer immunity through T-cell activation and have become the standard of care in patients with pretreated advanced lung cancer and have even replaced chemotherapy as first-line treatment in selected patients. Expression of PD-ligand-1 (PD-L1) has emerged as a biomarker that enriches the chance of response to these agents, which is consistent across most studies [8, 60] . Agents currently approved for the treatment of lung cancer by the US FDA include PD-1 inhibitors nivolumab and pembrolizumab, and PD-L1 inhibitor atezolizumab. Other agents are in development and may be approved in the near future, such as durvalumab. Two economic evaluations of nivolumab in the secondline setting have been reported (Table 4 ). One study focused on patients with squamous cancer in Canada, using two distinct models: a partitioned survival model and a Markov model [61] . Both models yielded similar results, with an ICER of Can$151,560/QALY compared with docetaxel and Can$140,601/QALY compared with erlotinib. Changes in utility values and average body weight had the greatest impact in one-way sensitivity analyses. The second study focused on patients with non-squamous carcinoma in Switzerland with stratification by various PD-L1 positivity thresholds [62] . The Markov model for this study compared strategies in which all patients receive nivolumab, all patients receive docetaxel or all patients undergo PD-L1 testing and only patients with tumours with high PD-L1 expression receive nivolumab (with a higher chance of response and clinical benefit). Using a biomarker-directed strategy, the ICERs were CHF 133,267/QALY at a treatment threshold of PD-L1 [1% and CHF 124,891/QALY at a treatment threshold of PD-L1[10%, using docetaxel as the standard comparator. The differences observed highlight the potential to enhance clinical benefit through biomarker selection with PD-L1 tumour expression. Currently, nivolumab is approved for all patients with NSCLC who have not responded to first-line chemotherapy.
An American study evaluated second-line pembrolizumab, another PD-1 inhibitor, compared with docetaxel using PD-L1[50% as the biomarker threshold and a 20-year time horizon [63] . The ICER reported was US$168,619/QALY, and shortening the time horizon from 20 to 5 years increased the ICER to US$194,884/QALY. Extrapolation of expected overall survival and time receiving pembrolizumab treatment had the greatest impact in sensitivity analysis.
Since the publication of these studies, pembrolizumab has emerged as an approved first-line therapy in those with Unless otherwise stated the outcome measure for the ICER is the QALY ICER incremental cost-effectiveness ratio, LYG life-year gained, NSCLC non-small-cell lung cancer Currency conversion is estimated based on the historical exchange rate provided based on the period average from the month of publication of the article. Currency exchange rates were obtained from: http://www.oanda.com/currency/historical-rates/ PDL-1 positive tumours (C50%), replacing chemotherapy as the first-line treatment in up to a third of patients with advanced NSCLC [60] . Nivolumab remains an option after first-line chemotherapy failure in unselected patients [6, 7] , and is believed to be less toxic than second-line docetaxel chemotherapy even in the population with no PD-L1 tumour expression.
Novel Approaches to Molecular Testing in Advanced Non-Small-Cell Lung Cancer
Additional biomarkers beyond EGFR and ALK (e.g. ROS-1, PD-L1) are now being integrated into routine practice as companion diagnostic assays to novel targeted therapies. In anticipation of the development of future predictive biomarkers and the need for analysing multiple concurrent biomarkers, multiplexed biomarker screening is an appealing practical approach. An American group reported on the cost effectiveness of a multiplexed testing approach, comparing a test-treat strategy when targeted therapy was initiated after multiplex test results for EGFR and ALK were available against a no testing strategy where all patients received standard chemotherapy [64] . The ICER for the test-treat strategy was US$136,000/QALY, with the authors concluding this met the willingness-to-pay threshold in USA. Alternate strategies of empiric treatment with chemotherapy while multiple test results were pending, followed by a switch to TKI therapy when results were available, yielded less favourable ICERs. This analysis took a unique approach by accounting for the potential administration of multiple different targeted agents rather than a single TKI. Given that healthcare systems need to account for multiple possible treatment pathways and the associated costs for patients newly diagnosed with advanced NSCLC, performing economic analyses with this approach may give helpful insights into overall lung cancer treatment costs for payers. In response to these clinical needs, the uptake of multiplex testing technologies such as next-generation sequencing is increasing. An analysis of multiple targeted sequencing panels in the fourth-line setting conducted by an Australian group concluded that multiple targeted sequencing was not cost effective compared with chemotherapy or to best supportive care, with an ICER of $489,338 AUD/QALY and $485,199/LYG respectively [65] . However, the costeffectiveness of using next-generation sequencing in the first-line setting has not yet been reported.
Discussion
Health technology assessment of novel agents in lung cancer will have an increasingly important role as healthcare systems face quickly rising overall treatment costs, multiple emerging targets and even more new therapies. Molecular testing and biomarker analyses need to be integrated into economic evaluations of targeted therapies. By selecting patients expressing the appropriate biomarkers, molecular testing impacts the ICER for subsequent targeted therapy by restricting use to the population most likely to derive benefit. The targeted biomarker-based testand-treat strategy consistently reported more favourable ICERs compared with treating an unselected population [10, 19, 20] . However, high drug costs can still elevate the ICER above acceptable thresholds [42] .
Another consideration in evaluating economic analyses is sponsorship of the study as well as the country of origin. Discrepant conclusions regarding the cost effectiveness of the same targeted agent in the same country of origin have Unless otherwise stated the outcome measure for the ICER is the QALY Currency conversion is estimated based on the historical exchange rate provided based on the period average from the month of publication of the article. Currency exchange rates were obtained from: http://www.oanda.com/currency/historical-rates/ ICER incremental cost-effectiveness ratio, NSCLC non-small-cell lung cancer, PD-L1 programmed death ligand 1, TPS Tumour Proportion Score been reported in industry-sponsored studies compared with non-industry-sponsored studies [35] . Indeed, agencies such as NICE in conducting health technology assessments often adjust manufacturer submitted models and analyses, leading to revised ICER estimates of the agent under review. In addition, different jurisdictions will have different thresholds for what is considered cost effective or acceptable at a societal level. Therefore, comparing conclusions about cost effectiveness between studies conducted in different countries should be interpreted with caution.
Other important considerations include practice variations among countries or jurisdictions, such as outpatient vs. inpatient care or treatment delivery, which may also impact costs. Finally, patent expiry and emergence of generic drugs and less expensive technology over time will also significantly impact costs, and hopefully will change conclusions about the affordability of different treatment approaches in this era of precision medicine [66] .
Most jurisdictions worldwide face a common challenge of how to sustainably pay for novel therapies in lung and other cancers, despite the high costs of molecular testing and treatment. The availability of novel therapies for patients with lung cancer relies heavily on payer funding decisions, as drug prices are often prohibitive for most patients. Particularly for financially disadvantaged patients, options for accessing expensive novel treatments outside of time-limited patient assistance programmes and clinical trials are scarce. Therefore, healthcare payers face a daunting challenge of developing sustainable long-term funding arrangements to ensure that the maximum number of patients with lung cancer can access and derive clinical benefit from novel treatments.
Among the different challenges during the patient's journey of cancer treatment, financial distress is an important factor on the patients and their families. Ramsey et al. studied the association of financial distress on health outcomes among patients with different cancers, and they found a consistent positive association between filing for bankruptcy and earlier mortality [67] . The cumulative incidence of bankruptcy and mortality for the four most common cancers (breast, colorectal, lung and prostate) stratified by stage at diagnosis was significant. Surprisingly, lung cancer had the highest cumulative incidence of bankruptcy and the worst overall survival.
Conclusions
When evaluating economic analyses of novel lung cancer therapies, key factors influencing results include comparators chosen, perspective used, magnitude of clinical benefit, utility weighting of outcomes and drug acquisition costs. Other important factors include study sponsorship and country of origin as resource availability and patterns of practice may vary widely between jurisdictions. Molecular testing is an integral component of individualising treatment for NSCLC and biomarker-driven decision making should be integrated into cost evaluations. Though healthcare payers worldwide are challenged with increasing costs of molecular testing and novel agents for NSCLC, optimising molecular testing through approaches such a high-throughput next-generation sequencing and negotiating affordable drug acquisition costs are strategies to ensure that breakthroughs in therapy are affordable and available to patients with lung cancer.
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